| Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation E Pallagi, R Ambrus, P Szabó-Révész, I Csóka International journal of pharmaceutics 491 (1-2), 384-392, 2015 | 111 | 2015 |
| Study of thermal behaviour of sugar esters A Szűts, E Pallagi, G Regdon Jr, Z Aigner, P Szabó-Révész International journal of pharmaceutics 336 (2), 199-207, 2007 | 71 | 2007 |
| Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach K Karimi, E Pallagi, P Szabó-Révész, I Csóka, R Ambrus Drug design, development and therapy, 3331-3343, 2016 | 66 | 2016 |
| Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes I Csóka, E Pallagi, TL Paál Drug Discovery Today 23 (7), 1340-1343, 2018 | 60 | 2018 |
| New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach E Pallagi, K Karimi, R Ambrus, P Szabó-Révész, I Csóka International journal of pharmaceutics 511 (1), 151-160, 2016 | 55 | 2016 |
| Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development E Pallagi, R Ismail, TL Paál, I Csóka European Journal of Pharmaceutical Sciences 122, 160-169, 2018 | 51 | 2018 |
| Quality by design based formulation study of meloxicam-loaded polymeric micelles for intranasal administration B Sipos, P Szabó-Révész, I Csóka, E Pallagi, DG Dobó, P Bélteky, ... Pharmaceutics 12 (8), 697, 2020 | 41 | 2020 |
| Aerodynamic properties and in silico deposition of isoniazid loaded chitosan/thiolated chitosan and hyaluronic acid hybrid nanoplex DPIs as a potential TB treatment M Mukhtar, E Pallagi, I Csóka, E Benke, Á Farkas, M Zeeshan, K Burián, ... International Journal of Biological Macromolecules 165, 3007-3019, 2020 | 36 | 2020 |
| Development of meloxicam-human serum albumin nanoparticles for nose-to-brain delivery via application of a quality by design approach G Katona, GT Balogh, G Dargó, R Gáspár, Á Márki, E Ducza, ... Pharmaceutics 12 (2), 97, 2020 | 36 | 2020 |
| New thermogravimetric protocol for the investigation of normal and damaged human hyaline cartilage G Sohár, E Pallagi, P Szabó-Révész, K Tóth Journal of thermal analysis and calorimetry 89, 853-856, 2007 | 36 | 2007 |
| Application of the QbD-based approach in the early development of liposomes for nasal administration E Pallagi, O Jójárt-Laczkovich, Z Németh, P Szabó-Révész, I Csóka International journal of pharmaceutics 562, 11-22, 2019 | 33 | 2019 |
| Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach C Bartos, E Pallagi, P Szabó-Révész, R Ambrus, G Katona, T Kiss, ... European Journal of Pharmaceutical Sciences 123, 475-483, 2018 | 31 | 2018 |
| Preliminary study of nanonized lamotrigine containing products for nasal powder formulation P Gieszinger, I Csóka, E Pallagi, G Katona, O Jójárt-Laczkovich, ... Drug Design, Development and Therapy, 2453-2466, 2017 | 30 | 2017 |
| Further characterization of degenerated human cartilage with differential scanning calorimetry K Tóth, G Sohár, E Pallagi, P Szabó-Révész Thermochimica acta 464 (1-2), 75-77, 2007 | 29 | 2007 |
| Pegylation and formulation strategy of Anti-Microbial Peptide (AMP) according to the quality by design approach R Manteghi, E Pallagi, G Olajos, I Csóka European Journal of Pharmaceutical Sciences 144, 105197, 2020 | 28 | 2020 |
| A proposed methodology for a risk assessment-based liposome development process Z Németh, E Pallagi, DG Dobó, I Csóka Pharmaceutics 12 (12), 1164, 2020 | 21 | 2020 |
| Quality-by-design-based development of n-propyl-gallate-loaded hyaluronic-acid-coated liposomes for intranasal administration F Sabir, G Katona, E Pallagi, DG Dobó, H Akel, D Berkesi, Z Kónya, ... Molecules 26 (5), 1429, 2021 | 17 | 2021 |
| Iron (II) sulfate release from drop-formed lipophilic matrices developed by special hot-melt technology E Pallagi, K Vass, K Pintye-Hódi, P Kása Jr, G Falkay, I Erős, ... European journal of pharmaceutics and biopharmaceutics 57 (2), 287-294, 2004 | 16 | 2004 |
| An updated risk assessment as part of the QbD-based liposome design and development Z Németh, E Pallagi, DG Dobó, G Kozma, Z Kónya, I Csóka Pharmaceutics 13 (7), 1071, 2021 | 15 | 2021 |
| Regulatory considerations, challenges and risk-based approach in nanomedicine development I Csóka, R Ismail, O Jójárt-Laczkovich, E Pallagi Current Medicinal Chemistry 28 (36), 7461-7476, 2021 | 9 | 2021 |
